Antiplatelet Drug: Clopidogrel



Antiplatelet Drug: Clopidogrel
QUESTION
Select an antiarrhythmic, antiplatelet, or anticoagulant medication. Share the mechanism of action of this medication and hints for monitoring, side effects, and drug interactions, including interactions with CAM, of which one should be aware. Discuss evidence and treatment guidelines to determine appropriate therapeutic options for a patient with a cardiovascular disorder. Include the name of the medication in the subject line so that the medications can be followed. Make sure you choose a different medication from your peers. Include references using APA format.
Antiplatelet Drug: Clopidogrel

ANSWER

Topic 6 DQ 1

Student’s Name
Institutional Affiliation
Course Code and Name
Professor’s Name
Date

Topic 6 DQ 1
Clopidogrel is an antiplatelet drug indicated to reduce the formation of blood clots in patients with peripheral heart disease, vascular disease, coronary artery diseases, or patients that have received a coronary intervention (“Clopidogrel,” 2022). Mechanism of action: Clopidogrel works primarily by irreversibly binding its active metabolite to the P2Y12 ADP receptors on platelets. The binding prevents ADP from binding on the P2Y12 receptors, thus preventing aggregation of platelets forming blood clots. Monitoring at baseline: Maximum serum concentration reaches after half an hour to an hour of oral administration. Monitor effectiveness by stimulating platelets with ADP to measure platelet reactivity and reading the results using light transmission aggregometry, ELIZA, flow cytometry, or any other approved platelet function tests (Alvitigala et al., 2020). Side effects include diarrhea, nosebleeds, extreme fatigue, nausea, vomiting, and stomach pains (“Clopidogrel: MedlinePlus drug information,” 2020). Adverse reactions reported include bloody vomit, unusual bleeding or easy bruising, changes in vision, shortness of breath, and adverse allergic reactions like swelling of the face, tongue, feet, and difficulty breathing.
Drug interactions: Clopidogrel may interact with diabetes drugs, stomach acid drugs, blood thinners, non-steroidal anti-inflammatory drugs, opioids, salicylates, and blood thinners. It is also contraindicated with abrocitinib, ritonavir, and dasabuvir (“Clopidogrel: MedlinePlus drug information,” 2020). CAM interactions: Danshen, evening promise, garlic, Ginko bibola, and saw palmetto (Mayo Staff, 2020). Appropriate therapeutic options for patients with a cardiovascular disorder: Secondary prevention in patients with cerebrovascular disease and acute coronary syndrome, clopidogrel, and aspirin are used to reduce future risks of cardiovascular events (Passacquale et al., 2022). Dosage ranges from 75mg to 300mg. Additionally, clopidogrel monotherapy yielded better results than other antiplatelet drugs in treating cerebrovascular disease.
Clopidogrel is an antiplatelet drug used to reduce the formation of blood clots in patients with peripheral heart disease, vascular disease, coronary artery diseases, or patients that have received a coronary intervention. Contraindicated in patients under particular medication and monitoring effectiveness of the drug gives information of drug interaction with other medication.  
References
Alvitigala, B. Y., Gooneratne, L. V., Constantine, G. R., Wijesinghe, R. A., & Arawwawala, L. D. (2020). Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy. Pharmacology Research & Perspectives, 8(6). https://doi.org/10.1002/prp2.686
Clopidogrel. (2022, June 4). DrugBank Online | Database for Drug and Drug Target Info. https://go.drugbank.com/drugs/DB00758
Clopidogrel: MedlinePlus drug information. (2020, December 15). MedlinePlus – Health Information from the National Library of Medicine. https://medlineplus.gov/druginfo/meds/a601040.html
Mayo Staff. (2020, November 14). Herbal supplements and heart medicines may not mix. Mayo Clinic. https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/herbal-supplements/art-20046488
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022). Antiplatelet therapy in cardiovascular disease: Current status and future directions. British Journal of Clinical Pharmacology, 88(6), 2686-2699. https://doi.org/10.1111/bcp.15221

Antiplatelet Drug: Clopidogrel


Scroll to Top